融券方面，中国黄金2月9日融券偿还2.77万股，融券卖出5200.00股，按当日收盘价计算，卖出金额6.01 万元；融券余量31.31万股，融券余额361.94万元，超过近一年90%分位水平，处于高位。 资料显示，中国黄金集团黄金珠宝股份有限公司位于北京市东城区安外大街柳荫公园南街1号，成立日 期2010年12月16日，上市日期2021年2月5日，公司主营业务涉及中国黄金是国内专业从事"中国黄金"品 牌黄金珠宝产品研发、设计、生产、销售、品牌运营的大型企业,是中国黄金集团黄金珠宝零售板块的 唯一平台,是我国黄金珠宝销售领域知名的中央企业。主营业务收入构成为：黄金产品98.83%，品牌使 用费0.67%，管理服务费0.22%，其他业务0.15%，K金珠宝类产品0.13%。 2月9日，中国黄金涨1.23%，成交额14.84亿元。两融数据显示，当日中国黄金获融资买入额8724.84万 元，融资偿还9412.33万元，融资净买入-687.49万元。截至2月9日，中国黄金融资融券余额合计4.06亿 元。 机构持仓方面，截止2025年9月30日，中国黄金十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股175 ...

来源：新浪证券-红岸工作室 2月9日，洛阳钼业涨1.96%，成交额42.36亿元。两融数据显示，当日洛阳钼业获融资买入额3.76亿元， 融资偿还3.61亿元，融资净买入1524.89万元。截至2月9日，洛阳钼业融资融券余额合计47.47亿元。 融资方面，洛阳钼业当日融资买入3.76亿元。当前融资余额47.23亿元，占流通市值的1.21%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，洛阳钼业2月9日融券偿还44.36万股，融券卖出6.14万股，按当日收盘价计算，卖出金额 137.66万元；融券余量106.84万股，融券余额2395.35万元，超过近一年80%分位水平，处于高位。 截至9月30日，洛阳钼业股东户数30.42万，较上期增加28.08%；人均流通股0股，较上期增加0.00%。 2025年1月-9月，洛阳钼业实现营业收入1454.85亿元，同比减少5.99%；归母净利润142.80亿元，同比增 长72.61%。 分红方面，洛阳钼业A股上市后累计派现215.62亿元。近三年，累计派现105.76亿元。 机构持仓方面，截止2025年9月30日，洛阳钼业十大流通股东中，香港中央结算有限公司位居第 ...

Market Overview - The Shanghai Composite Index rose by 1.41% to close at 4123.09 points, with a daily high of 4123.16 points [1] - The Shenzhen Component Index increased by 2.17% to close at 14208.44 points, reaching a high of 14211.7 points [1] - The ChiNext Index saw a rise of 2.98%, closing at 3332.77 points, with a peak of 3340.33 points [1] Margin Trading and Securities Lending - The total margin trading and securities lending balance in the Shanghai and Shenzhen markets was 26,556.13 billion yuan, with a financing balance of 26,387.82 billion yuan and a securities lending balance of 168.31 billion yuan, reflecting an increase of 6.15 billion yuan from the previous trading day [2] - The Shanghai market's margin trading balance was 13,475.12 billion yuan, up by 4.76 billion yuan, while the Shenzhen market's balance was 13,081.01 billion yuan, increasing by 1.39 billion yuan [2] - A total of 3,480 stocks had financing funds for purchase, with the top three being Xinyi Technology (25.36 billion yuan), Zhongji Xuchuang (24.32 billion yuan), and Shenghong Technology (17.14 billion yuan) [2][3] Fund Issuance - Eight new funds were issued yesterday, including: - Shangyin Stable and Wise Three-Month Holding (FOF) C - Xinyuan CSI Hong Kong Stock Connect Technology Index C - Xinyuan CSI Hong Kong Stock Connect Technology Index A - Shangyin Stable and Wise Three-Month Holding (FOF) A - CITIC Construction Investment Shuangyi Three-Month Holding Period Bond A - Zhaoshang Yutian Mixed Initiation C - CITIC Construction Investment Shuangyi Three-Month Holding Period Bond C - Zhaoshang Yutian Mixed Initiation A [4][5] Top Net Purchases on the Dragon and Tiger List - The top ten net purchases on the Dragon and Tiger list were led by: - Zhongwen Online with a net purchase of 715.97 million yuan - TCL Zhonghuan with 517.15 million yuan - Zhongchao Holdings with 406.27 million yuan - Hunan Silver with 354.37 million yuan - Jiecheng Shares with 230.40 million yuan [6][7]

来源：新浪证券-红岸工作室 2月9日，春立医疗跌0.35%，成交额3498.88万元。两融数据显示，当日春立医疗获融资买入额524.38万 元，融资偿还376.73万元，融资净买入147.65万元。截至2月9日，春立医疗融资融券余额合计4854.82万 元。 融资方面，春立医疗当日融资买入524.38万元。当前融资余额4852.98万元，占流通市值的0.73%，融资 余额超过近一年90%分位水平，处于高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非洲、大洋洲及欧洲等多个 国家和地区。主营业务收入构成为：医疗器械产品99.89%，其他(补充)0.11%。 截至9月30日，春立医疗股东户数6164.00，较上 ...

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight increase in stock price and has reported its financial performance, indicating growth in revenue and net profit [1][2]. - As of February 9, Weigao Blood Purification's stock price increased by 0.47%, with a trading volume of 36.10 million yuan. The financing buy-in amount was 5.05 million yuan, while the financing repayment was 7.37 million yuan, resulting in a net financing buy of -2.32 million yuan [1]. - The total balance of margin trading for Weigao Blood Purification as of February 9 is 120 million yuan, which accounts for 7.56% of its circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, a decrease of 20.95% from the previous period. The average circulating shares per person increased by 26.51% to 1,535 shares [2]. - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].

Group 1 - The core viewpoint of the news is that Laplace has shown significant trading activity and financial performance, indicating a strong position in the market [1][2] - On February 9, Laplace's stock price increased by 0.97%, with a trading volume of 2.286 billion yuan, and a net financing purchase of approximately 81.50 million yuan [1] - As of February 9, the total margin balance for Laplace reached 761 million yuan, with a financing balance of 759 million yuan, accounting for 4.72% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Laplace was 8,774, a decrease of 8.38% from the previous period, while the average circulating shares per person increased by 9.14% to 4,138 shares [2] - For the period from January to September 2025, Laplace reported a revenue of 4.321 billion yuan, reflecting a year-on-year growth of 0.43%, and a net profit attributable to shareholders of 588 million yuan, with a growth of 2.07% [2] - Since its A-share listing, Laplace has distributed a total of 150 million yuan in dividends [2]

Group 1 - On February 9, 2024, Ugreen Technology's stock rose by 3.65%, with a trading volume of 313 million yuan. The margin trading data indicated a financing purchase amount of 18.12 million yuan and a financing repayment of 24.38 million yuan, resulting in a net financing buy of -6.26 million yuan. As of February 9, the total margin trading balance for Ugreen Technology was 111 million yuan [1] - The financing balance for Ugreen Technology on February 9 was 110 million yuan, accounting for 0.77% of the circulating market value. This financing balance is above the 90th percentile level over the past year, indicating a high level [1] - On the same day, Ugreen Technology had no shares repaid or sold in the securities lending market, with a remaining quantity of 8,900 shares and a securities lending balance of 585,600 yuan, also exceeding the 90th percentile level over the past year [1] Group 2 - Ugreen Technology, established on March 16, 2012, is located in Longhua District, Shenzhen, Guangdong Province. The company specializes in the research, design, production, and sales of 3C consumer electronics, providing comprehensive digital solutions. Its main product categories include charging products (37.01%), transmission products (26.64%), audio and video products (16.34%), storage products (10.75%), mobile peripheral products (7.88%), and others (1.33%) [2] - As of January 30, 2025, Ugreen Technology had 10,800 shareholders, an increase of 2.93% from the previous period, with an average of 15,236 circulating shares per person, a decrease of 2.84% [2] - For the period from January to September 2025, Ugreen Technology achieved a revenue of 6.364 billion yuan, representing a year-on-year growth of 47.80%, and a net profit attributable to shareholders of 467 million yuan, with a year-on-year increase of 45.08% [2] Group 3 - Ugreen Technology has distributed a total of 373 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, among the top ten circulating shareholders of Ugreen Technology, the largest shareholder was the "Fuguo Small and Medium Cap Selected Mixed A/B" fund, holding 2.3574 million shares, an increase of 1.3456 million shares from the previous period. The "Hong Kong Central Clearing Limited" was the tenth largest shareholder, holding 2.0036 million shares, an increase of 660,000 shares [3] - Several funds, including "Fuguo Innovation Trend Stock A" and "Wanjia Growth Enterprise Board 2-Year Regular Open Mixed A," have exited the top ten circulating shareholders list [3]

Group 1 - The core viewpoint of the news is that Jiangsu Pioneer Precision Technology Co., Ltd. has shown significant trading activity and financial performance, with a focus on its financing and stockholder dynamics [1][2][3] Group 2 - As of February 9, 2024, Pioneer Precision's stock price increased by 1.56%, with a trading volume of 181 million yuan. The financing buy-in amount was 26.86 million yuan, while the net financing buy-in was 5.89 million yuan, indicating strong investor interest [1] - The total financing and securities lending balance for Pioneer Precision reached 384 million yuan, accounting for 5.28% of its market capitalization, which is above the 90th percentile of the past year [1] - The company reported a revenue of 969 million yuan for the first nine months of 2025, representing a year-on-year growth of 11.47%, while the net profit attributable to shareholders decreased by 7.56% to 162 million yuan [2] Group 3 - Pioneer Precision has distributed a total of 40.48 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, the number of shareholders decreased by 5.02% to 12,400, while the average circulating shares per person increased by 5.29% to 3,268 shares [2] - The top shareholders include the Jiashi Shanghai Stock Exchange Science and Technology Innovation Board Chip ETF, which holds 921,500 shares, and the Southern Science and Technology Innovation Board 3-Year Open Mixed Fund, which holds 712,900 shares [3]

Group 1 - The core viewpoint of the news is that Hong Sifang has shown significant trading activity with a notable increase in financing and margin trading, indicating a high level of investor interest [1][2]. - As of February 9, Hong Sifang's financing balance reached 176 million yuan, accounting for 8.84% of its market capitalization, which is above the 90th percentile of the past year [1]. - The company reported a revenue of 2.481 billion yuan for the first nine months of 2025, a year-on-year decrease of 6.94%, and a net profit of 45.8423 million yuan, down 59.02% year-on-year [2]. Group 2 - Hong Sifang's main business revenue composition includes 92.93% from compound fertilizers, 5.07% from nitrogen fertilizers, 1.22% from potassium sulfate, and 0.79% from other products [1]. - As of September 30, 2025, the number of shareholders decreased by 5.10% to 25,300, while the average circulating shares per person increased by 5.38% to 2,117 shares [2]. - The top circulating shareholder is the Southern CSI 1000 ETF, holding 711,200 shares, a decrease of 13,400 shares from the previous period [2].

分红方面，金天钛业A股上市后累计派现3885.00万元。 机构持仓方面，截止2025年9月30日，金天钛业十大流通股东中，博时创新经济混合A（010994）位居 第六大流通股东，持股71.29万股，相比上期减少2174.00股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 2月9日，金天钛业涨1.15%，成交额7138.86万元。两融数据显示，当日金天钛业获融资买入额740.55万 元，融资偿还906.40万元，融资净买入-165.85万元。截至2月9日，金天钛业融资融券余额合计2.34亿 元。 融资方面，金天钛业当日融资买入740.55万元。当前融资余额2.33亿元，占流通市值的5.20%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，金天钛业2月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量812.00股，融券余额1.57万元，超过近一年90%分位水平，处于高位。 资料 ...